PTSD

America’s VetDogs 5K Run & Dog Walk Joins Suffolk County Veterans Run Series

Retrieved on: 
Thursday, April 4, 2024
RET, Disability studies, Veteran, Dog, Partnership, Post-traumatic stress disorder, Sag Harbor, New York, Scherer, County, Disability, Suicide, PTSD

The Suffolk County Veterans Runs Series (SCVRS) will offer a variety of events in 2024, each in honor of our nation’s and region’s veterans.

Key Points: 
  • The Suffolk County Veterans Runs Series (SCVRS) will offer a variety of events in 2024, each in honor of our nation’s and region’s veterans.
  • “We thank the Scherer family and all the event organizers for welcoming America’s VetDogs into the Suffolk County Veterans Run Series,” said John Miller, president and CEO, America’s VetDogs and the Guide Dog Foundation.
  • “As we honor Chris Scherer’s enduring legacy and all our courageous veterans and service members, we eagerly anticipate witnessing the collective spirit of camaraderie as participants, both human and canine, take to the streets of Smithtown on September 28.”
    “On behalf of the Scherer family and the steering committee of the Suffolk County Veterans Run Series, we are thrilled to welcome the America’s VetDogs 5K Run and Dog Walk to the 2024 series,” said Tim Scherer, Suffolk County Veterans Run Series.
  • Congratulations to the America’s VetDogs organization and we look forward to a great 2024 run series!”
    Marcelle Leis, CMSgt (Ret), USAF/NYANG, director, Suffolk County Veterans Services Agency, Office of the County Executive, said: “We are excited to have America’s VetDogs join the Suffolk County Veteran Run Series this year.

Lava for Good Podcasts Garners Webby Nominations for 'The War on Drugs' and Honors for 'Earwitness'

Retrieved on: 
Thursday, April 4, 2024
War on Drugs, Webby Awards, Depression, Music, Partnership, Name, Public, Dignity, Humour, Human, Season, Season 2, Justice, War, Good, Pain management, Legislation, Sport, Miscarriage, Public service, PTSD, Entertainment

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Lava for Good Podcasts is honored by the latest accolades in the digital world.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Lava for Good Podcasts is honored by the latest accolades in the digital world.
  • The latest recognition for The War on Drugs is particularly timely, as Lava for Good has commenced production of Season 2 for release this fall.
  • These nominations and honors add to Lava for Good’s long list of accolades, including past recognition at the Webby Awards, Ambie Awards, Signal Awards, and iHeartPodcast Awards.
  • For more information on The War on Drugs, Earwitness, and other Lava for Good podcasts, visit www.lavaforgood.com or find them on all popular podcast platforms.

Brain & Behavior Research Foundation Awards Distinguished Investigator Grants Valued at $1 Million to 10 Scientists Pursuing Innovative Mental Health Research

Retrieved on: 
Thursday, April 4, 2024
Depression, Patient, Mitochondrion, Doctor of Science, Harvard University, Therapy, Research, Risk, Mental health, University of Pittsburgh, Brain, DSM-IV codes, Brown University, Cannabis, Memory, Safety, Spectrum, Mitophagy, Schizophrenia, Hippocampus, Bipolar disorder, Anxiety, Learning, University, Psychopathology, Cerebrospinal fluid, University of California, Distinguishing, PET, Biomarker, Hope, Baylor College of Medicine, Behavior, AMPA, Fragile X syndrome, PTSD, Pharmaceutical industry

New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.

Key Points: 
  • New York, April 04, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) today announced it is awarding Distinguished Investigator Grants valued at $1 million to 10 senior-level scientists who are conducting innovative projects in neurobiological and behavioral research.
  • By funding transformative research focused on new ways to prevent, diagnose, and treat psychiatric disorders, our Distinguished Investigator Grants are encouraging established scientists to continue advancing our understanding of mental illness and disorders of brain and behavior,” says Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation.
  • The ground-breaking work of the Distinguished Investigator Grant recipients will bring hope and healing to people and families impacted by mental illness.
  • We applaud these scientists for their extraordinary dedication, innovation, and leadership.”
    Recipients of the Distinguished Investigator Grants are full professors at research institutions in the United States and abroad.

Connections Wellness Group first outpatient mental health provider to offer Cognia-accredited private school education at no cost to all its patients

Retrieved on: 
Tuesday, April 2, 2024
IOP, Depression, Certification, PHP, Learning, CWG, Education, Patient, School, Accreditation, Mental health, Child, Anxiety, Suicidal ideation, Self-harm, Health, PTSD, Teaching, Nursing

This accreditation allows patients as young as 8 to receive fully transferable school credits while enrolled in a CWG intensive day therapy treatment program to improve their mental health and well-being.

Key Points: 
  • This accreditation allows patients as young as 8 to receive fully transferable school credits while enrolled in a CWG intensive day therapy treatment program to improve their mental health and well-being.
  • We firmly believe a child’s education should not suffer while in behavioral health treatment,” said Christopher Bennett, vice president of education at CWG.
  • “Our intensive day therapy program provides a unique opportunity for patients to receive both necessary mental health treatment and fundamental education.”
    The mission of Connections Wellness Group is to provide life-enriching care that connects patients to long-term wellness.
  • CWG teachers are state-licensed or have advanced degrees, which enhances their ability to provide education to patients in different settings.

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Citadel, Depression, Department of Defence, National War College, Legislation, Government, Army Command, Veteran, Veterans' affairs, General counsel, Patient, Insomnia, Colonel, TBI, Policy, Senior counsel, University, Anxiety, Military personnel, Military, Traumatic brain injury, OGC, National Security Strategy, Private law, PTSD, Nursing

HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).

Key Points: 
  • HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).
  • Nexalin’s Advisory Board provides strategic advice and counsel to support the Company’s advancement of its non-invasive, frequency-based, deep-brain stimulation devices in U.S. military and government agencies.
  • Mr. Hudson is a partner in Tully Rinckey PLLC’s Washington, D.C. office where he focuses his practice on military, security clearance, and federal employment law.
  • Mark White, CEO of Nexalin Technology stated, “We are honored to welcome Col. Bill Hudson to the Military & Government Advisory Board.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, April 2, 2024
Vagus nerve, Central nervous system, Fibromyalgia, Patent, TBI, Anxiety, Software, United States patent law, ElectroCore, PTSD, Medical device

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).

Key Points: 
  • ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO).
  • The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology:
    US Patent No.
  • The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
  • The electrical impulses are bursts of 2 to 20 sinusoidal pulses.

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, Depression, Congress, PD, Patient, OUD, CIAS, Sale, G&A, DMT, Șaeș, Pivotal, Psilocybin, Atai, TRD, Investment, Ibogaine, Pharmacokinetics, Safety, PTSD, OTF, Pharmaceutical industry

“In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.

Key Points: 
  • “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc., streamlining clinical, general and administrative operations.
  • atai realized operational efficiencies by simplifying and optimizing its organizational structure in line with its revised business and pipeline priorities.
  • In August 2023, the Phase 1 study results demonstrated that 9 mg/kg of oral ibogaine leads to robust psychedelic experiences.

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Retrieved on: 
Thursday, March 28, 2024
MEG, Development, Psychiatry, Veteran, Physician, Post-traumatic stress disorder, NSI, Analysis of variance, Patient, UC, RPQ, Jesse Russell, Radiology, Human services, PCS, Concussion, Trial of the century, University, McGill Pain Questionnaire, Brain damage, Pain, ANOVA, Vaccine, PTSD, MPQ, Medical imaging

HOUSTON, TEXAS, March 28, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the positive results of a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, and is further detailed in an abstract co-authored by the United States Department of Veterans Affairs (VA) San Diego Healthcare System, and the Radiology, Psychiatry and Neurosciences Departments of UC San Deigo.

Key Points: 
  • mTBI is a leading cause of sustained physical, cognitive, emotional, and behavioral deficits in veterans and the general public.
  • However, the underlying pathophysiology is not completely understood, and there are few effective treatments for post-concussive symptoms (PCS).
  • The study was conducted as a randomized, double-blind, placebo-controlled clinical trial over an eight-week period, with two groups being examined: an active tACS group and a sham tACS group.
  • Mark White, CEO of Nexalin Technology, stated, "We are encouraged by the results of the clinical study, reinforcing the significant reduction in pain and other persistent symptoms of mild traumatic brain injury among veteran patients.

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

Canine Companions® Launches the CanineAlert™ Device

Retrieved on: 
Monday, April 8, 2024
Statistics, Vibration, Device, ROSA, Veteran, Bed, Anxiety, Night, Human, Hypervigilance, Nightmare, Dog, Disability, Patent, PTSD, Vaccine

SANTA ROSA, Calif., April 8, 2024 /PRNewswire/ -- Canine Companions®, the nonprofit organization that transforms the lives of children, adults, and veterans with disabilities, by providing them with expertly trained service dogs free of charge, announces the launch of the groundbreaking CanineAlert™ Device. For many veterans, PTSD-induced nightmares are a debilitating aspect of daily life impacting sleep quality, overall well-being and daily functioning. Canine Companions® expertly trained service dogs already support veterans experiencing PTSD but the addition of this device alerts the service dogs earlier and enables them to interrupt PTSD episodes earlier, leading to a shorter recovery period process. The CanineAlert™ Device integrates state-of-the-art technology with the specialized training of Canine Companions® service dogs, offering a more comprehensive solution to the traumatic nightmares experienced by veterans living with the symptoms of PTSD.

Key Points: 
  • The CanineAlert™ Device integrates state-of-the-art technology with the specialized training of Canine Companions® service dogs, offering a more comprehensive solution to the traumatic nightmares experienced by veterans living with the symptoms of PTSD.
  • The CanineAlert™ Device, developed and patented by Canine Companions® in-house team, monitors the wearer's heart rate and wirelessly communicates with a collar device worn by the service dog.
  • "Our CanineAlert™ Device is a significant advancement in mitigating the impacts of PTSD," says Paige Mazzoni, CEO of Canine Companions®.
  • Canine Companions® developed the CanineAlert™ Device to improve upon one of the most popular skills among Canine Companions® service dogs, the ability to recognize active nightmares and intervene by pulling off blankets or otherwise waking their humans and interrupting the episode.